Cargando…

Clinical Outcomes for Patients With Metastatic Breast Cancer Treated With Immunotherapy Agents in Phase I Clinical Trials

BACKGROUND: Immuno-oncology (IO) agents have demonstrated efficacy across many tumor types and have led to change in standard of care. In breast cancer, atezolizumab and pembrolizumab were recently FDA-approved in combination with chemotherapy specifically for patients with PD-L1-positive metastatic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schreiber, Anna R., Kagihara, Jodi A., Weiss, Jennifer A., Nicklawsky, Andrew, Gao, Dexiang, Borges, Virginia F., Kabos, Peter, Diamond, Jennifer R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010246/ https://www.ncbi.nlm.nih.gov/pubmed/33816286 http://dx.doi.org/10.3389/fonc.2021.640690

Ejemplares similares

Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center
por: Weiss, Jennifer A., et al.
Publicado: (2020)

Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval
por: Stoen, Ericson, et al.
Publicado: (2021)

Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study
por: Schreiber, Anna R., et al.
Publicado: (2021)

A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer
por: Diamond, Jennifer R., et al.
Publicado: (2018)

Paraneoplastic Encephalitis Associated with Locally Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
por: Shay, Rebecca C., et al.
Publicado: (2020)

Phase 0 Radiopharmaceutical–Agent Clinical Development
por: Kunos, Charles A., et al.
Publicado: (2020)

Recent Advances in Immunotherapy in Metastatic NSCLC
por: Bansal, Pranshu, et al.
Publicado: (2016)

Complete Pathologic Responses With Immunotherapy in Metastatic Renal Cell Carcinoma: Case Reports
por: Tucker, Matthew D., et al.
Publicado: (2020)

Phase II Clinical Trial of Robotic Stereotactic Body Radiosurgery for Metastatic Gynecologic Malignancies
por: Kunos, Charles A., et al.
Publicado: (2012)

Perspectives on Immunotherapy of Metastatic Colorectal Cancer
por: Dai, Yongjiu, et al.
Publicado: (2021)

Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer
por: Ionkina, Anastasia A., et al.
Publicado: (2017)

Case Report: Clinical Characteristics and Outcomes of HIV Positive Patients With Metastatic Prostate Cancer Treated With Immunotherapy: A Case Series and Literature Review
por: Idossa, Dame, et al.
Publicado: (2022)

Complete remission with immunotherapy: Case report of a patient with metastatic bladder cancer to the humerus
por: Abdelhakam, D., et al.
Publicado: (2020)

A case of metastatic renal cell carcinoma with concomitant Castleman's disease treated with immunotherapy
por: Lozar, Taja, et al.
Publicado: (2021)

Abscopal effect in metastatic breast cancer treated with stereotactic body radiotherapy in the absence of immunotherapy
por: Kim, Jae Sik, et al.
Publicado: (2023)

Review of Bone Modifying Agents in Metastatic Breast Cancer
por: Raghu Subramanian, Charumathi, et al.
Publicado: (2021)

Clinical opportunities in combining immunotherapy with radiation therapy
por: Finkelstein, Steven E., et al.
Publicado: (2012)

Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer
por: Raimondi, Alessandra, et al.
Publicado: (2020)

The Promise of Liquid Biopsy to Predict Response to Immunotherapy in Metastatic Melanoma
por: Fattore, Luigi, et al.
Publicado: (2021)

Interaction Between Modern Radiotherapy and Immunotherapy for Metastatic Prostate Cancer
por: Ollivier, Luc, et al.
Publicado: (2021)

Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Hsieh, Ronan W., et al.
Publicado: (2021)

The Prognostic Value of Pre-treatment Hemoglobin (Hb) in Patients With Advanced or Metastatic Gastric Cancer Treated With Immunotherapy
por: Gou, Miaomiao, et al.
Publicado: (2021)

IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma Patients
por: Tobin, Richard P., et al.
Publicado: (2019)

Toward Maximizing Immunotherapy in Metastatic Castration-Resistant Prostate Cancer – Rationale for Combinatorial Approaches Using Chemotherapy
por: Slovin, Susan R.
Publicado: (2012)

Cancer Immunotherapy and Next-Generation Clinical Immune Assessment
por: Ma, Chao, et al.
Publicado: (2014)

Dissociated Response in Metastatic Cancer: An Atypical Pattern Brought Into the Spotlight With Immunotherapy
por: Humbert, Olivier, et al.
Publicado: (2020)

Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma—A Retrospective Study
por: Hadash-Bengad, Reut, et al.
Publicado: (2020)

Impact of Hepatitis Virus on the Feasibility and Efficacy of Anticancer Agents in Patients With Hepatocellular Carcinoma in Phase I Clinical Trials
por: Koyama, Takafumi, et al.
Publicado: (2019)

Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan
por: Yu, Kenneth H., et al.
Publicado: (2021)

Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials
por: Lopez, Juanita, et al.
Publicado: (2015)

Molecular Immunotherapy: Promising Approach to Treat Metastatic Colorectal Cancer by Targeting Resistant Cancer Cells or Cancer Stem Cells
por: Forster, Stefan, et al.
Publicado: (2020)

Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy
por: Trojaniello, Claudia, et al.
Publicado: (2021)

Monitoring Regulatory Immune Responses in Tumor Immunotherapy Clinical Trials
por: Olson, Brian M., et al.
Publicado: (2013)

Glioblastoma Organoids: Pre-Clinical Applications and Challenges in the Context of Immunotherapy
por: Klein, Eliane, et al.
Publicado: (2020)

Editorial: Genomics and Epigenomics of Cancer Immunotherapy: Challenges and Clinical Implications
por: Abedalthagafi, Malak
Publicado: (2021)

Microenvironment and the progress of immunotherapy in clinical practice of NSCLC brain metastasis
por: Xie, Mengqing, et al.
Publicado: (2023)

Second-Line Systemic Treatment for Metastatic Urothelial Carcinoma: A Network Meta-Analysis of Randomized Phase III Clinical Trials
por: Yoon, Hyun Sik, et al.
Publicado: (2019)

A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer
por: Huang, Jia-Yi, et al.
Publicado: (2023)

Unbiased Phenotype-Based Screen Identifies Therapeutic Agents Selective for Metastatic Prostate Cancer
por: Chung, Ivy, et al.
Publicado: (2021)

Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade
por: Olsen, T. Anders, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dd2jjo6e0t7h92qhg9nkbd9tgt